Expression of Her-2/neu in extrahepatic cholangiocarcinoma

Figures & data

Table 1 Patients’ clinicopathologic characteristics

Age at diagnosis (years)	Gender	Diagnosis	Tumor size (cm)	Tumor grade	Tumor stage
48	F	Cholangiocarcinoma	1.5	Moderately differentiated	pT2N0MX
50	F	Cholangiocarcinoma	1.7	Moderately differentiated	pT1N0M0
56	F	Cholangiocarcinoma	3.0	Moderately differentiated	pT1N0M0
57	F	Cholangiocarcinoma	2.0	Well differentiated	pT1N0M0
57	F	Cholangiocarcinoma	2.0	Moderately differentiated	pT3N0MX
58	F	Cholangiocarcinoma	3.0	Well differentiated	pT3N0MX
60	F	Cholangiocarcinoma	1.2	Moderately differentiated	pT3N1MX
61	F	Cholangiocarcinoma	1.7	Moderately differentiated	pT1N0MX
61	F	Cholangiocarcinoma	1.5	Moderately differentiated	pT2N1MX
62	F	Cholangiocarcinoma	3.5	Poorly differentiated	pT3N1MX
62	F	Cholangiocarcinoma	0.5	Well differentiated	pT3N0MX
63	F	Cholangiocarcinoma	3.1	Moderately differentiated	pT2N0MX
66	F	Cholangiocarcinoma	1.7	Well differentiated	pT3N1MX
66	F	Cholangiocarcinoma	2.0	Moderately differentiated	pT3N0MX
66	F	Cholangiocarcinoma	1.7	Poorly differentiated	pT1N1MX
69	F	Cholangiocarcinoma	1.5	Poorly differentiated	pT1N1MX
75	F	Cholangiocarcinoma	2.2	Moderately differentiated	pT3N1MX
77	F	Cholangiocarcinoma	2.0	Poorly differentiated	pT3N1MX
78	F	Cholangiocarcinoma	2.4	Moderately differentiated	pT3N1MX
82	F	Cholangiocarcinoma	1.8	Poorly differentiated	pT3N1MX
89	F	Cholangiocarcinoma	1.8	Moderately differentiated	pT3N0MX
67	F	Cholangiocarcinoma	1.5	Moderately differentiated	pT3N0MX
41	M	Cholangiocarcinoma	1.7	Poorly differentiated	pTxNxM1
58	M	Cholangiocarcinoma	1.4	Poorly differentiated	pT3N0MX
58	M	Cholangiocarcinoma	1.3	Poorly differentiated	pT2N1MX
59	M	Cholangiocarcinoma	2.5	Moderately differentiated	pT2N0MX
61	M	Cholangiocarcinoma	1.8	Well differentiated	pT3N1MX
61	M	Cholangiocarcinoma	3.0	Moderately differentiated	pT3N1MX
64	M	Cholangiocarcinoma	2.0	Poorly differentiated	pT2N1MX
65	M	Cholangiocarcinoma	2.2	Well differentiated	pT1N0MX
66	M	Cholangiocarcinoma	1.0	Moderately differentiated	pT2N0MX
68	M	Cholangiocarcinoma	2.0	Well differentiated	pT2N0MX
68	M	Cholangiocarcinoma	2.5	Well differentiated	pT3N1MX
70	M	Cholangiocarcinoma	1.5	Moderately differentiated	pT1N1MX
70	M	Cholangiocarcinoma	1.3	Moderately differentiated	pT2N0MX
73	M	Cholangiocarcinoma	2.5	Moderately differentiated	pT2N0MX
73	M	Cholangiocarcinoma	1.5	Moderately differentiated	pT3N0MX
76	M	Cholangiocarcinoma	1.6	Moderately differentiated	pT2N0MX
79	M	Cholangiocarcinoma	0.5	Well differentiated	pT4N0MX
80	M	Cholangiocarcinoma	1.5	Moderately differentiated	pT3N1MX
83	M	Cholangiocarcinoma	0.7	Moderately differentiated	pT2N0MX
84	M	Cholangiocarcinoma	3.7	Moderately differentiated	pT3N0MX
74	F	Cholangiocarcinoma	1.9	Moderately differentiated	pT3N1MX

Abbreviations: F, female; M, male.

Figure 1 Extrahepatic Cholangiocarcinoma and Her-2/neu testing.

Notes: (A) A well-differentiated to moderately differentiated adenocarcinoma of the bile duct showing an invasive tumor with papillary morphology and associated desmoplastic stroma. The tumor cells have pink cytoplasm and elongated to polygonal nuclei with anisocytosis and loss of polarity (hematoxylin and eosin, 40×). (B) The adenocarcinoma shown in Figure 1A is strongly and diffusely positive for Her-2/neu (3+) and exhibits a well-defined membranous pattern of stain (40×). (C) Dual in situ hybridization demonstrating amplification of human epidermal growth factor receptor-2 in a moderately differentiated adenocarcinoma.

Table 2 Her-2/neu antibodies used in the current study compared to others

Author	Method	Antibody source
Kim et al (2007)^Citation18	Manual	Zymed lab, South San Francisco, CA, USA
Yoshikawa et al (2008)^Citation16	Automated (polymer-based method, EnVision + Dual Link System-HRP)	Dako Denmark A/S, Glostrup, Denmark
Zheng and Zhu (2007)^Citation19	Manual	Dako Denmark A/S, Glostrup, Denmark
Nakazawa et al (2005)^Citation17	Manual	Nichirei, Tokyo, Japan
Shamekh et al (present study)	Automated (Ventana Medical Systems, using the Benchmark XT)	Ventana Medical Systems, Inc. Tucson, AZ, USA

Abbreviations: Her-2, human epidermal growth factor receptor-2; HRP, horseradish peroxidase.

Kim HJ, Yoo TW, Park DI, et al. Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node-positive patients. Ann Oncol. 2007;18(5):892–897.

 Web of Science ®Google Scholar

Yoshikawa D, Ojima H, Iwasaki M, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008;98(2):418–425.

 PubMed Web of Science ®Google Scholar

Zheng J, Zhu YM. Expression of c-erbB-2 proto-oncogene in extrahepatic cholangiocarcinoma and its clinical significance. Hepatobiliary Pancreat Dis Int. 2007;6(4):412–415.

 PubMed Web of Science ®Google Scholar

Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol. 2005;206(3):356–365.

 PubMed Web of Science ®Google Scholar